logo
#

Latest news with #FutureReady

Department of Community Development announces second edition of the Social Care Forum
Department of Community Development announces second edition of the Social Care Forum

Zawya

time10-07-2025

  • Health
  • Zawya

Department of Community Development announces second edition of the Social Care Forum

Abu Dhabi – As part of the Year of the Community, and in line with Abu Dhabi's ongoing efforts to strengthen the social care ecosystem and foster strategic dialogue aimed at enhancing quality of life, the Department of Community Development – Abu Dhabi has announced the second edition of the Social Care Forum. Under the theme 'Future-Ready Social Care: People, Practice, and Policy ,' the forum will take place on 24–25 September at Hilton Yas Abu Dhabi As the largest event of its kind in the Emirate, the forum will bring together leading experts, decision-makers, and local and international specialists in the social sector to explore key trends and developments in this vital field, aligning with the objectives of the Year of the Community 2025 The forum builds on the remarkable success of its first edition launched by the Department in 2024, which served as a strategic platform for social care stakeholders to address key challenges and opportunities, and contributed to strengthening Abu Dhabi's integrated social care system. It aims to support ongoing efforts to enhance quality of life through developing social policies and services and exchanging global experiences and best practices Mubarak Al Ameri, Executive Director of the Licensing and Social control Sector at the Department of Community Development, said that the first edition of the Social Care Forum served as a pioneering regional platform that brought together a wide range of local and international professionals and enriched strategic dialogue based on knowledge and practical experience. 'In this second edition, we continue to build on that momentum by deepening the discussions and expanding participation around the future of the social care system,' he added. He mentioned that this year's forum focuses on key themes including the future of social policies, workforce empowerment, data-driven practices, as well as the role of partnerships, technology, and innovation in developing sustainable social solutions. The forum also aligns with the objectives of the Year of the Community 2025 through supporting families and communities and enhancing social cohesion and well-being The second edition of the forum will highlight a wide range of essential topics that align with future trends in the social care sector, including the role of governments in shaping the future of care, the impact of digital transformation and artificial intelligence on service delivery and its implications for social care professionals and institutions, the empowerment of specialized workforces, and the strengthening of public-private partnerships. It will also explore emerging social issues such as child protection and family cohesion, while emphasizing the importance of adopting inclusive and evidence-based care models that meet the needs of all community groups, including children, youth, senior citizens, and families The forum will also focus on topics such as attracting young talent, promoting supportive work environments, and developing proactive support programs that cover different life stages. It will explore successful global experiences in social policy and dedicate space to showcasing the work of field professionals and presenting innovative models that can be applied in practice Interactive sessions will feature hands-on presentations and direct audience discussions addressing various topics such as elder care, family empowerment, youth development, and the measurement of social policy impact. The forum will also offer a specialized training program through certified tracks covering critical topics including the use of artificial intelligence in social care services, child protection and early risk detection, trauma-informed case management, and child and parent-centered family care. These programs represent a valuable opportunity to enhance the competencies of social care professionals and develop their practical skills within a long-term professional development journey The Social Care Forum reflects the Department of Community Development's commitment to building a safe and inclusive social environment in Abu Dhabi by developing policies and programs based on global best practices and activating collaboration frameworks and knowledge exchange to drive meaningful impact and build a modern social system that enhances quality of life for all members of society. -Ends- About the Department of Community Development The Department of Community Development – Abu Dhabi was established in 2018 with the aim of regulating and overseeing the social sector through the development of legislation, policies, strategies, standards, and operational systems to enhance quality of life and ensure dignity for all community members. The Department provides high-quality and efficient social services that meet the needs of all segments of society and seeks to raise awareness, foster knowledge, and create innovative solutions to address priority social challenges You can follow the Department's social media accounts on: Twitter / Instagram / Facebook / YouTube @DCDAbuDhabi

Boys & Girls Clubs joins movement to help youth become 'future ready'
Boys & Girls Clubs joins movement to help youth become 'future ready'

Yahoo

time10-06-2025

  • Business
  • Yahoo

Boys & Girls Clubs joins movement to help youth become 'future ready'

The Boys & Girls Clubs of Central Carolina announced recently its official commitment to Future Ready, a strategic direction launched by Boys & Girls Clubs of America to meet the urgent needs of today's youth and shape the future of youth development nationwide. The Future Ready movement unites more than 1,000 local Boys & Girls Club organizations under a shared mission: to empower young people with the skills, experiences and support they need to thrive in school, work and life. As the challenges facing youth continue to evolve—from mental health struggles and academic disruption to economic uncertainty and the digital divide—BGCCC is stepping forward with an ambitious local plan to grow impact and deepen community leadership. Local Goals for 2028• Increase average daily attendance from 338 to 500 • Grow registered membership from 1,129 to 1,500 • Expand teen membership from 177 to 275 'Our commitment to Future Ready is more than a pledge—it's a promise to the kids and teens in our communities,' said Fallon Brewington, CEO of Boys & Girls Clubs of Central Carolina. 'We are creating spaces where young people are safe, supported and empowered to build their brightest futures.' Five Strategic Priorities• Organizational strength: BGCCC is investing in the professional development of its board and leadership team, with an emphasis on recruitment, onboarding and volunteer retention. • Talent development: Staff and volunteers will benefit from enhanced training, onboarding, and compensation strategies to strengthen our culture of excellence. • Youth & Teen Impact: BGCCC is launching new initiatives to increase teen engagement, including plans to open a Teen Workforce Development Center in Siler City by 2028. • Influence: With the recent hire of a director of resource development & marketing, BGCCC is actively working to build brand awareness and elevate youth voices in local conversations. • Digital transformation: Technology upgrades for staff and members are underway to improve the Club experience and operations across all sites. BGCCC encourages supporters, partners and community leaders to join in this transformational work. Whether through advocacy, philanthropy or volunteering, every effort helps bring our communities—and our youth—closer to being Future Ready.

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

Yahoo

time10-06-2025

  • Health
  • Yahoo

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase inhaled insulin at the American Diabetes Association's (ADA) 85th Scientific Sessions from June 20-23 in Chicago. Dr. Michael J. Haller, Professor and Chief of Pediatric Endocrinology at the University of Florida, will present the results from the randomized period of the INHALE-1 clinical trial during a 'Future Ready' symposium. Dr. Haller is the Chair for MannKind's Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age). The presentation/posters planned at ADA's 85th Scientific Sessions regarding the most recent advances in inhaled insulin treatment include: Symposium – Future Ready – Breakthrough in Pediatric Type 1 Diabetes Care Sunday, June 22 – 1:30 to 3:00 p.m. (Central) in Room W 181(A-C)Dr. Michael J. Haller will present: From Discovery to Treatment – Latest Updates on Inhaled Insulin Treatment Patient Reported Outcomes with Use of Inhaled Technosphere Insulin (T1) (Board 827)Saturday, June 21, 2025 – 12:30 to 1:30 p.m. (Central) Presenter: Dr. Peter Calhoun Efficacy and Safety of Prandial Technosphere Inhaled Insulin (Afrezza) Compared with Placebo in Adult Individuals with T2DM – Results from a Phase III Clinical Trial from India (Board No. 833)Saturday, June 21, 2025 – 12:30 to 1:30 p.m. (Central) Presenter: Dr. K M Prasanna Kumar Additionally, MannKind will host booth #1617 in the Exhibit Hall throughout the ADA's Scientific Sessions. Members of MannKind's Medical Education Team will be available for scientific exchange in the medical section of the booth. For more information about ADA's Scientific Sessions programming, and/or to register to attend the conference, please visit: MannKind expects to issue the topline results from the full study pediatric data set with safety extension in 2Q 2025 and anticipates submitting a Supplemental Biologics License Application in mid-2025 for a potential pediatric indication for Afrezza. About MannKindMannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life. Please visit to learn more, and follow us on LinkedIn, Facebook, X or Instagram. Forward-Looking StatementsThis press release contains forward-looking statements about a planned release of scientific data and a potential sBLA submission for Afrezza that involves risks and uncertainties. Words such as 'believes', 'anticipates', 'plans', 'expects', 'intends', 'will', 'goal', 'potential' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that issues that develop in the preparation of data releases and filings may subject us to unanticipated delays as well as other risks detailed in MannKind's filings with the Securities and Exchange Commission, including under the 'Risk Factors' heading of its Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release. AFREZZA and MANNKIND are registered trademarks of MannKind Corporation. CONTACT: MannKind Contacts: Media Relations Christie Iacangelo, (818) 292-3500 Email: media@ Investor Relations Ana Kapor, (818) 661-5000 Email: ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

Yahoo

time09-06-2025

  • Health
  • Yahoo

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase inhaled insulin at the American Diabetes Association's (ADA) 85th Scientific Sessions from June 20-23 in Chicago. Dr. Michael J. Haller, Professor and Chief of Pediatric Endocrinology at the University of Florida, will present the results from the randomized period of the INHALE-1 clinical trial during a 'Future Ready' symposium. Dr. Haller is the Chair for MannKind's Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age). The presentation/posters planned at ADA's 85th Scientific Sessions regarding the most recent advances in inhaled insulin treatment include: Symposium – Future Ready – Breakthrough in Pediatric Type 1 Diabetes Care Sunday, June 22 – 1:30 to 3:00 p.m. (Central) in Room W 181(A-C)Dr. Michael J. Haller will present: From Discovery to Treatment – Latest Updates on Inhaled Insulin Treatment Patient Reported Outcomes with Use of Inhaled Technosphere Insulin (T1) (Board 827)Saturday, June 21, 2025 – 12:30 to 1:30 p.m. (Central) Presenter: Dr. Peter Calhoun Efficacy and Safety of Prandial Technosphere Inhaled Insulin (Afrezza) Compared with Placebo in Adult Individuals with T2DM – Results from a Phase III Clinical Trial from India (Board No. 833)Saturday, June 21, 2025 – 12:30 to 1:30 p.m. (Central) Presenter: Dr. K M Prasanna Kumar Additionally, MannKind will host booth #1617 in the Exhibit Hall throughout the ADA's Scientific Sessions. Members of MannKind's Medical Education Team will be available for scientific exchange in the medical section of the booth. For more information about ADA's Scientific Sessions programming, and/or to register to attend the conference, please visit: MannKind expects to issue the topline results from the full study pediatric data set with safety extension in 2Q 2025 and anticipates submitting a Supplemental Biologics License Application in mid-2025 for a potential pediatric indication for Afrezza. About MannKindMannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life. Please visit to learn more, and follow us on LinkedIn, Facebook, X or Instagram. Forward-Looking StatementsThis press release contains forward-looking statements about a planned release of scientific data and a potential sBLA submission for Afrezza that involves risks and uncertainties. Words such as 'believes', 'anticipates', 'plans', 'expects', 'intends', 'will', 'goal', 'potential' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that issues that develop in the preparation of data releases and filings may subject us to unanticipated delays as well as other risks detailed in MannKind's filings with the Securities and Exchange Commission, including under the 'Risk Factors' heading of its Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release. AFREZZA and MANNKIND are registered trademarks of MannKind Corporation. CONTACT: MannKind Contacts: Media Relations Christie Iacangelo, (818) 292-3500 Email: media@ Investor Relations Ana Kapor, (818) 661-5000 Email: ir@ in to access your portfolio

Vallous International Launches Energy Efficiency Initiative Aligned with Singapore Green Plan 2030
Vallous International Launches Energy Efficiency Initiative Aligned with Singapore Green Plan 2030

Associated Press

time09-06-2025

  • Business
  • Associated Press

Vallous International Launches Energy Efficiency Initiative Aligned with Singapore Green Plan 2030

SINGAPORE - Media OutReach Newswire - 9 June 2025 - Vallous International has announced the launch of its Energy Efficiency Initiative, a bold step toward building resilient, future-ready infrastructure in alignment with the Singapore Green Plan 2030. Vallous International Launches Energy Efficiency Initiative Aligned with Singapore Green Plan 2030 Transforming Infrastructure for the Future This programme targets organisations across Singapore, ranging from commercial & industrial buildings to data centres. The objective is to enhance their performance in sustainability, energy efficiency, and operational resiliency. Recognising that power resiliency is now a strategic business enabler rather than a mere technical function, Vallous International aims to address critical challenges, such as outdated systems, fragmented vendor environments, and rising sustainability demands. Many existing infrastructures fall short of today's carbon-conscious standards and are not equipped to handle modern AI workloads or grid instabilities. 'Our clients need intelligent, integrated systems that can keep operations running 24/7 while promoting energy efficiency,' said Matthew Kee, Head of Solutions & Operations at Vallous International. 'We saw a clear opportunity to support businesses with brand-agnostic, full-service infrastructure solutions that are sustainable, resilient, and future-proof.' Key Goals and Measurable Impact Vallous International adopts a continuous improvement approach—Plan, Measure, Review, Refine—to help clients achieve and exceed their energy-saving targets. The company will track the success of this initiative through these key metrics: Real-World Results and Community Impact Initial implementations have already shown results: Focusing on UPS data centres, this project marked a 12-month uptime record with a 30% reduction in energy usage and Green Mark certification. Enabled smaller enterprises to enhance critical infrastructure with reduced downtime and improved customer satisfaction scores. As these projects scale, Vallous anticipates lower energy consumption across Singapore's commercial sectors. This should be achieved without compromising business continuity or end-user experience. Stakeholder and Ecosystem Engagement Employee engagement is central to the initiative's success, with internal teams and partners encouraged to share success stories and champion sustainability goals. Vallous International also strengthens its ecosystem approach by working closely with OEMs, SMEs, and public agencies to deliver integrated, multi-vendor infrastructure solutions. 'This energy efficiency initiative is more than just a CSR exercise; it also offers a strategic advantage,' as revealed by Peggy Chng, Managing Director at Vallous International. 'Aligned with our sustainability priorities, this initiative boosts our brand reputation and deepens client trust. We would also like to thank our partners for multiplying the positive impact.' Future Outlook With this initiative, Vallous reinforces its commitment to supporting business continuity and environmental leadership. In line with the Singapore Green Plan 2030, the company looks to set a precedent for how technology and sustainability can intersect to drive meaningful, scalable change. Hashtag: #VallousInternational #SustainableInnovation #GreenPlan2030 The issuer is solely responsible for the content of this announcement. About Vallous International Pte Ltd Vallous International specialises in critical power solutions, data centre engineering, IT infrastructure, connectivity, and maintenance support. The company supports the core operations of digitally focused organisations through resilient, future-ready technology and infrastructure.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store